1.70

0.29% 0.00

Engene Therapeutics Inc (ENGN)

Overview News Price History Financials Discussions Forecast

Engene Therapeutics Inc stock is traded at $1.70, with a volume of 402.78K. It is up +0.29% in the last 24 hours and down -6.32% over the past month. enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Previous Close:

$1.70

Open:

$1.72

24h Volume:

402.78K

Relative Volume:

0.36

Market Cap:

$113.88M

Revenue:

Net Income/Loss:

$-122.44M

P/E Ratio:

-0.7542

EPS:

-2.254

Net Cash Flow:

$-103.79M

1W Performance:

-2.57%

1M Performance:

-6.32%

6M Performance:

-82.76%

1Y Performance:

-53.67%

1-Day Range:

$1.69

$1.73

1-Week Range:

$1.66

$1.83

52-Week Range:

$1.40

$12.25

Engene Therapeutics Inc Stock (ENGN) Company Profile

Name

Engene Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(514) 332-4888

Address

4868 RUE LEVY, SUITE 220, SAINT-LAURENT

Employee

Twitter

Next Earnings Date

2026-09-10

Latest SEC Filings

ENGN's Discussions on Twitter

Compare ENGN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENGN Engene Therapeutics Inc	1.70	113.88M	0	-122.44M	-103.79M	-2.254
VRTX Vertex Pharmaceuticals Inc	515.89	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.79	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.45	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.83	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.81	39.31B	5.76B	514.49M	1.10B	4.4813

Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	WBB Securities	Buy
Jan-30-26	Initiated	Jefferies	Buy
Nov-11-25	Upgrade	Raymond James	Outperform → Strong Buy
Feb-18-25	Initiated	Piper Sandler	Overweight
Feb-14-25	Downgrade	UBS	Buy → Neutral
Dec-23-24	Initiated	H.C. Wainwright	Buy
Nov-27-24	Initiated	Raymond James	Outperform
Nov-18-24	Initiated	JMP Securities	Mkt Outperform
Aug-28-24	Initiated	Oppenheimer	Outperform
Apr-22-24	Initiated	Wells Fargo	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Mar-28-24	Initiated	UBS	Buy
Mar-08-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	Leerink Partners	Outperform

View All

Engene Therapeutics Inc Stock (ENGN) Latest News

Aug 15, 2026

enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView

Aug 15, 2026

enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan

Aug 14, 2026

enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan

Aug 14, 2026

Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan

Aug 14, 2026

Aug 13, 2026

Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan

Aug 13, 2026

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat

Aug 13, 2026

Aug 12, 2026

Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan

Aug 12, 2026

enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com

Aug 12, 2026

Aug 11, 2026

enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks

Aug 11, 2026